Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gemini Therapeutics logo — Pioneering precision treatments for genetic eye diseases wit...

Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships.

Founded 2015 Post Ipo Equity Total: $139.50M Biopharma, Biotechnology +1

General Information

Company Name Gemini Therapeutics
Founded Year 2015
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Gemini Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Gemini Therapeutics

Gemini Therapeutics, established in 2015, is a precision medicine company that focuses on developing innovative therapeutics for genetically defined dry age-related macular degeneration (AMD) and related rare genetic conditions. Their diverse pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies which target molecular abnormalities in patients with significant clinical needs. The company has secured a $95.00M Post-IPO Equity investment on 08 February 2021 from a notable list of investors including Atlas Venture, Lightstone Ventures, Boxer Capital, Wellington Management, Acorn Bioventures, Fidelity, Foresite Capital, Suvretta Capital Management, DAFNA Capital Management, LLC, and Alyeska Investment Group. The company's slogan, "Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships," reflects its commitment to leveraging global academic collaborations to advance potentially groundbreaking therapeutic solutions. With its focus on Biopharma, Biotechnology, and Health Care industries, Gemini Therapeutics is positioned to make significant contributions to the precision medicine landscape.

Taxonomy: Precision Medicine, Genetic Eye Diseases, Therapeutics, Molecular Abnormalities, Monoclonal Antibodies, Recombinant Proteins, Gene Therapies, Rare Genetic Conditions, Dry Age-Related Macular Degeneration, Pipeline Development, Academic Collaborations, Life Science Investors, Innovation, First-in-Class Therapeutics, Global Partnerships

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
08 Feb 2021
Series A •••••• - 17 Oct 2017
Seed Round •••••• - 19 Apr 2016

Gemini Therapeutics Alternatives & Competitors

Gemini Therapeutics vs
Stylus Medicine
Stylus Medicine United States

Developing transformative in vivo genetic medicines

48 employees
Biotechnology, SaaS
Gemini Therapeutics vs
miRecule, Inc.
miRecule, Inc. United States

RNA Therapeutics

Seed
12 employees
Biopharma, Biotechnology
Gemini Therapeutics vs
Moonwalk Biosciences
Moonwalk Biosciences United States

Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic i...

Series A
21 employees
AI, Biopharma

FAQ About Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships.
Gemini Therapeutics was founded in 2015.
Gemini Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care.
Gemini Therapeutics has completed 3 funding rounds, raising a total of $139.50M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Gemini Therapeutics include Stylus Medicine, miRecule, Inc., Moonwalk Biosciences, GenEdit, Carbon Biosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gemini Therapeutics and Stylus Medicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Gemini Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy